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Background: Prior studies show that intramuscular injection and particle-mediated epidermal delivery of xenogeneic
melanosomal antigens (tyrosinase or Tyr, gp100) induce CD8+ T cell responses to the syngeneic protein. To further define
the optimal vaccination strategy, we conducted a phase I study of in vivo electroporation (EP) of a murine Tyr DNA
vaccine (pINGmuTyr) in malignant melanoma patients.
Methods: Human leukocyte antigen (HLA)-A1, A2, A24 or B35 stage IIb-IV melanoma patients received up to five doses
of the mouse tyrosinase DNA vaccine by EP every three weeks at dose levels of 0.2 mg, 0.5 mg, or 1.5 mg per injection.
Peripheral blood mononuclear cells (PBMC) were collected, cultured with a peptide pool containing eight HLA class
I-restricted Tyr-specific T-cell epitopes, and analyzed by HLA-A*0101-restricted tetramers and intracellular cytokine
staining (ICS).
Results: Twenty-four patients received ≥1 dose of the pINGmuTyr vaccine; PBMCs from 21 patients who completed all
five doses were available for Tyr immune assays. The only common toxicity was grade 1 injection site reaction. Six of 15
patients (40%) in the 1.5 mg dose cohort developed Tyr-reactive CD8+ T cell responses following stimulation, defined as
a ≥3 standard deviation increase in baseline reactivity by tetramer or ICS assays. No Tyr-reactive CD8+ T cell response
was detected in the 0.2 mg and 0.5 mg dose cohort patients. Epitope spreading of CD8+ T cell response to NY-ESO-1
was observed in one patient with vitiligo. One patient subsequently received ipilimumab and developed an enhanced
Tyr-reactive response with polyfunctional cytokine profile. After a median follow-up of 40.9 months, median survival has
not been reached.
Conclusions: A regimen of five immunizations with pINGmuTyr administered by EP was found to be safe and resulted
in Tyr-reactive immune responses in six of 15 patients at 1.5 mg dose cohort.
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While most early stage malignant melanomas can be cured
by surgical excision alone, the relapse rates of high-risk
melanomas (Breslow thickness >4 mm or loco-regional
metastases) remain high after surgery [1,2]. The only Food
and Drug Administration (FDA)-approved adjuvant ther-
apy for melanoma is high-dose interferon-α (IFN-α), which
consistently improves relapse-free survival, but not overall
survival, and is associated with significant toxicities [3,4].
Consequently, there is a strong interest in developing more
effective and better tolerated adjuvant therapies.
Melanoma is an attractive target for immunotherapy
because of its selective expression of differentiation antigens
not expressed by other tissues. Strategies to harness the im-
mune system against melanoma have included cytokine
therapy, immune-modulating antibodies, adoptive T-cell
therapy, and vaccines [5]. These efforts culminated in the
milestone approval of ipilimumab, a monoclonal antibody
against cytotoxic T-lymphocyte antigen-4 (CTLA-4), in
March 2011 for patients with refractory melanoma [6]. In
another disease setting, castrate-resistant prostate cancer, the
approval of Sipuleucel-T, a dendritic cell vaccine, demon-
strated that tumor vaccination strategies have the potential
to provide clinical benefit for advanced cancer patients [7].
Many different vaccination approaches have been
attempted in melanoma, including whole-cell vaccines,
peptide/protein-based vaccines, ganglioside vaccines,
dendritic-cell based therapy, recombinant viral vectors
and DNA vaccines [5]. DNA vaccines allow direct deliv-
ery of antigen into the MHC class I-processing pathway,
which is necessary to elicit cytotoxic T-cell responses
[8]. Other advantages of DNA vaccines include the low
cost and ease of manufacturing of the plasmid vector
and the potential ability of unmethylated CpG motifs in
the bacterial plasmid vector to stimulate the innate
branch of the immune system [8].
One potential target for a vaccine strategy is tyrosinase
(Tyr), a prototypical melanocytic differentiation antigen
that is expressed homogenously by most melanoma speci-
mens [9-11] and which elicits spontaneous CD8+ T cell re-
sponses [12-14]. DNA vaccines have elicited measurable
immune responses against Tyr and gp100, another mela-
nocytic differentiation antigen, in pre-clinical mouse
models [15], dogs with spontaneous melanoma [16-19],
and humans [20-22]. We have shown in pre-clinical mouse
models that immunization with DNA coding the xenogen-
eic orthologues of self-antigens is an effective strategy for
inducing immunologic responses and overcoming im-
munologic tolerance [23-25].
Based on studies performed by our group, a xenogeneic
(human) Tyr DNA vaccine was approved by the U.S.
Department of Agriculture for the treatment of melanoma
in dogs in 2007 [19]. Our group has also shown that
Tyr-reactive CD8+ T cell responses could be induced inmelanoma patients following administration regimens
comprising intramuscular (IM) injection of DNA plasmid
vectors encoding the human Tyr (pINGhuTyr) and mouse
Tyr (pINGmuTyr) [20]. The rationale for incorporating a
xenogeneic variant of Tyr in the immunization regimen
either before or after immunization with pINGhuTyr was
the potential to enhance immunogenicity due to the slight
divergence of polypeptide sequences between species [15].
Accumulated clinical experience in the field of DNA
based immunization indicates that an important challenge
in DNA vaccine development is the identification of an ef-
fective method for delivery. While DNA immunization by
conventional IM and intradermal injection have been uti-
lized in a wide range of disease indications, concerns re-
garding suboptimal potency have led to the evaluation of
alternative methods for delivery [26]. These methods in-
clude physical methods for enhancing intracellular DNA
delivery such as particle-mediated epidermal delivery
(PMED) of DNA-coated gold particles and in vivo electro-
poration (EP). EP involves injecting plasmid DNA solu-
tions into targeted tissues, followed by electric pulses that
transiently increase cell membrane permeability to facili-
tate intracellular uptake of the plasmids [8]. EP has been
demonstrated to increase expression of the delivered genes
in targeted tissues compared to conventional injection of
plasmid DNA alone and causes minimal tissue damage
[27]. In non-clinical [28] and clinical studies [29,30], EP
mediated DNA vaccine delivery has demonstrated signifi-
cant enhancement in the induction of cell mediated
immune responses.
In order to assess the potential for in vivo EP to enhance
IM delivery of the pINGmuTyr plasmid DNA vaccine, we
performed a phase I trial in human melanoma patients.
The objectives of the study were to characterize the safety
of the administration procedure at escalating DNA dose
levels as well as the resulting Tyr specific immunological
response. Although the previous clinical study of DNA
based Tyr immunization evaluated a combined syngeneic
and xenogeneic Tyr immunization regimen, the present
phase I study included only the xenogeneic pINGmuTyr
construct. The rationale for this was the favorable outcome
of the xenogeneic immunization in canine melanoma




Of the 24 patients enrolled on this trial, 21 received all five
vaccinations and were evaluable for immune responses and
survival. One patient (Tyr-20) withdrew informed consent,
another patient (Tyr-12) experienced progressive disease
(PD) after the second vaccination and the third patient (Tyr-
16) experienced syncope after the first vaccination and was
removed from the trial. Among the 21 evaluable subjects,
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the 0.5 mg dose level, and 15 at the 1.5 mg dose level.
Patient demographics are listed in Table 1. The me-
dian age of the patients was 60 and 71% were male.
All patients had a Karnofsky performance status ≥
90%. Most (67%) had resected stage III disease. All
eligible stage II-III patients had refused adjuvant IFN-
α therapy, after a thorough discussion with a phys-
ician investigator. One patient with recurrent stage IV
disease had previously been treated with adjuvant
IFN-α for resected stage IIB disease, developed recur-
rence while on IFN-α and had undergo resection of a
solitary lung metastasis. Other adjuvant therapies in-
cluded radiation (four patients, one with concurrent
temozolomide) and temozolomide as single-agent
(one patient) or with isolated limb infusion with
dactinomycin/melphalan (one patient). One patient
underwent radiofrequency ablation of a solitary liver
metastasis. 18 of 24 patients enrolled in this study




















Temozolomide alone 1 4.1%
Radiation alone 2 8.3%
RSA ablation 1 4.1%
Interferon 1 4.1%
Temozolomide + 1 4.1%
Radiation
Temozolomide + 1 4.1%
Isolated limb infusionpositive; Three were HLA-A2402 positive; one was
HLA-A25 and two were HLA-A03 as showed in
Table 2.
Adverse events and survival
The use of EP in the clinical setting was pretty feasible
and there were no logistic or technical issues associated
with its use in this study. There was minimal toxicity
noted for 24 patients. Only one patient (Tyr-16) in the
1.5 mg cohort experienced grade 3 syncope immediately
following administration of the first dose, with loss of
consciousness for approximately 30 seconds and dia-
phoresis, requiring hospitalization. This was deemed un-
likely to be related to vaccine toxicity and more likely of
vasovagal origin. The only other grade 1/2 toxicity noted
in >20% of patients was grade 1 injection site reaction
(46%). After a median period of 40.9 months, median
overall survival has not yet been reached.
Increase in tyrosinase-specific tetramer-reactive CD8+
T-cells after immunization
We performed multiparametric flow cytometry on patient
PBMC samples at baseline and after the third dose (Week
10) and fifth dose (Week 16) using tetramers for the
HLA-A*01 restricted peptides Tyr146-156 and Tyr243-251.
Tetramer analysis was restricted to the 14 patients who
were HLA-A*01 positive. There were not enough T cells
from patient Tyr-3 for tetramer staining. Four of the 14
patients (28.6%) had detectable tetramer-reactive CD8+ T
cells at either Weeks 10 or 16. Representative dot plots
from Patient Tyr-26 are shown in Figure 1, while Figure 2
describes the change in frequency of tetramer-reactive
CD8+ T cells for all 14 patients.
Phenotypic analysis of the tetramer-reactive CD8+ T cells
reflects an effector cell population
Chemokine receptor 7 (CCR7) and CD45RA are often used
to subtype the CD8+ T cell population, providing the fol-
lowing phenotypes: naïve cells (CCR7+CD45RA+), central
memory cells (CCR7+CD45RA−), effector memory cells
(CCR7−CD45RA−), and effector cells (CCR7−CD45RA+)
[31]. Tetramer-reactive CD8+ T cells from all three patients
were also CCR7lowCD45RAlow, consistent with an effector
phenotype (Figure 3).
In addition, it has been proposed that CD27 and CD28
are markers that further characterize the CCR7-CD45RA-
population into four subpopulations with different
effector/cytolytic function: EM1 (CD27+CD28+), EM2
(CD27+28-), EM3 (CD27-CD28-) and EM4 (CD27-CD28+)
[32]. The EM1 subtype has a phenotype very similar to the
CCR7+CD45RA- central memory cells, while the EM2 and
EM3 subtypes express mediators associated with effector
cells. CD27 expression was found to be intermediate in the
tetramer-reactive CD8+CCR7lowCD45RAlow population of
Table 2 Immune monitoring summary and clinical outcomes of patients who produced a measureable immune
response
Dose (mg) Patient HLA Type HLA/A*0101 Tetramer + CD8+ IFNγ+ Phenotype Tetramer+ CD8+ T cells*
0.2 Tyr-1 A0101 - -
Tyr-2 A1101 ND -
Tyr-3 A01 ND -
0.5 Tyr-4 A0101 - -
Tyr-5 A0101 - -
Tyr-6 A2501 ND -
1.5 Tyr-8 A2402 ND -
Tyr-9 A0101 + - CCR7low,CD45RAlow, CD27int, CD28int
Tyr-11 A0101 - -
Tyr-12# A02 ND ND
Tyr-13 A2402 ND -
Tyr-14 A0301/A2402 ND -
Tyr-16# A0101 ND ND
Tyr-18 A0101 - -
Tyr-19 A0101 - -
Tyr-20# A0101 ND ND
Tyr-21 A03 ND -
Tyr-22 A0101 - -
Tyr-23 A0101 - -
Tyr-24 A0101 - +
Tyr-25 A0101 - +
Tyr-26 A0101 + + CCR7low,CD45RAlow, CD27int, CD28low
Tyr-27 A0101 + - CCR7low,CD45RAlow, CD27int, CD28int
Tyr-28 A0101 + - CCR7low,CD45RAlow, CD27int, CD28int
* Low = 0–30%, intermediate (int) =30–60%, and high = 60–100% of cells that are tetramer positive. # Patient Tyr-12, 16 and 20 did not finish vaccine protocol.
ND = not done. “+” = Patients scored positive for tetramer-reactive CD8+ T cell or Tyr-reactive CD8+IFN-γ+ T cell response; “-” = Patients scored negative for
tetramer-reactive CD8+ T cell or Tyr-reactive CD8+IFN-γ+ T cell response.
Figure 1 Increase in tyrosinase243-251 HLA*A010-restricted
tetramer-reactive CD8+ T cells following mouse tyrosinase DNA
vaccination. Multiparameter flow cytometry was performed at
baseline, prior to the third vaccination (week 10) and after the fifth
vaccination (Week 16). Patient peripheral blood mononuclear cells
(PBMCs) were cultured for 10 days with a pool of tyrosinase
peptides. Representative dot plots from Patient Tyr-26 reveal an
increase in the frequency of tetramer-reactive CD8+ T cells in this
patient, with the peak at Week 10.
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activated T cells that are undergoing differentiation to
develop effector functionality. CD28 expression was inter-
mediate in two specimens and low in one specimen, also
consistent with the process of differentiation towards an
effector phenotype.Increases in CD8+IFN-γ+ T cells after immunization and
evidence of polyfunctionality
We next performed ICS to enumerate the intracellular
cytokine profile of CD8+ T cells in all 21 patients. Three
patients were found to have an increase in Tyr-reactive
CD8+IFN-γ+ T cells following immunization. Representa-
tive dot plots from Patient Tyr-25 are shown in Figure 4.
There was evidence of an increase not only in Tyr-reactive
CD8+ T cells that expressed IFN-γ but also evidence of
polyfunctional cytokine responses, consisting of combina-
tions of IFN-γ and MIP-1β, TNF-α and CD107a.
Figure 2 Changes in tyrosinase146-156 and tyrosinase243-251
HLA*A0101-restricted tetramer-reactive CD8+ T cells following
mouse tyrosinase DNA vaccination. Each point refers to the mean of
triplicate values. Most patients also underwent two peripheral blood
draws at baseline one week apart prior to receiving vaccination. The
values at baseline represent the mean of both of these time-points.
* Refers to patients with increase in tetramer-reactive CD8+ cells. (Patient
Tyr-9 scored positive for both Tyr tetramers, patient Tyr-26, 27 and
Tyr-28 had a single Tyr tetramer positive after vaccination).
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CD8+ T cells as well as a cytokine response in one of the
three patients (Patient Tyr-26).
Overall, six of the 15 patients at 1.5 mg dose level experi-
enced a Tyr-reactive CD8+ T-cell response after stimulationFigure 3 CCR7, CD45RA, CD27 and CD28 subpopulations in tyrosinase2
consistent with an effector phenotype. PMBCs were analyzed by tetramer
dot plots for CD3+CD8+ T cells of patient Tyr-26 at Week 16 show the expr
HLA*A0101 tetramer reactive CD8+ T cells (A). Further characterization in c
were CCR7-CD45RA-CD27loCD28mid, consistent with an effector phenotypewith the Tyr peptide epitope pool as detected by tetramer
or ICS analysis. No Tyr-reactive CD8+ T cell response was
detected in patients at 0.2 mg and 0.5 mg dose cohort. In
the responding patients, the increase from baseline to peak
response ranged from 1.5-fold to 2.8-fold in the tetramer
assay and from 2.1-fold to 3.3-fold in the ICS assay. Positive
responses were seen as early as at Week 10 and up to Week
16. All six patients with a CD8+ T cell response had
received the 1.5 mg dose. These data are summarized in
Figure 5 and Table 2.CTLA-4 blockade recalled Tyr-reactive CD8+ T cell responses
in a patient
Patient Tyr-25 was a 62-year-old man with a history
of multiple primary melanomas. He underwent a left
axillary lymph node dissection in October 2007 for
recurrent melanoma, followed by adjuvant chemoradi-
ation with temozolomide. He was then enrolled on
the DNA vaccine trial in April 2009 but developed
progressive disease after completing the trial. In Octo-
ber 2009, he initiated therapy with ipilimumab
10 mg/kg every three weeks for four doses. Because
the patient had developed a Tyr-reactive CD8+ T cell
response following vaccination, we quantified changes
in this response after he was treated with ipilimumab.
A significant increase in Tyr-reactive CD8+IFN-γ+ T
cells was detected after the second ipilimumab dose
(Figure 6). Unfortunately, he had rapidly progressive
disease and died in April 2010.43-251 HLA*A0101-restricted tetramer-reactive CD8
+ T cells are
assay after in vitro culture with tyrosinase peptide pool. Representative
ession of CCR7, CD45RA, CD28 and CD27 on tyrosinase243-251
ontour plots of CD3+CD8+tetramer+ T cells revealed that these cells
(B).
Figure 4 Increase in tyrosinase-reactive CD8+IFN-γ+ T cells following mouse tyrosinase DNA vaccination. Intracellular cytokine staining was
performed by multiparameter flow cytometry after culturing patient PBMCs with a tyrosinase peptide epitope pool for 10 days. These are
representative dot plots of CD3+CD8+ T cells from Patient Tyr-25 who had an increase in CD8+IFN-γ+ cells following vaccination. There was
evidence of polyfunctionality, including cells that were both IFN-γ+, and either CD107a+, MIP-1β+ or TNF-α+.
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during DNA vaccination.
Patient Tyr-2 was a 70-year-old woman with a history of
a resected melanoma of unknown primary site arising in
her left inguinal area. After receiving five doses of
the pINGmuTyr vaccine at the 0.2 mg dose level, she de-
veloped recurrent disease with vitiligo even though aγ
Figure 5 Changes in frequency of tyrosinase-reactive CD8+IFN-γ+ T cells
the mean of triplicate values in intracellular cytokine staining assays. Most p
week apart prior to receiving vaccination. The values at baseline represent
increase in CD8+ IFN-γ + T cells.Tyr-reactive CD8+IFN-γ+ T-cell response was not de-
tected after stimulation with the peptide epitope pool.
She was known to have pre-existing baseline antibody
titers against NY-ESO-1, a cancer-testis antigen. As
such, we characterized changes in NY-ESO-1 specific
immune responses. Following vaccination, she developed
a robust NY-ESO-1 specific CD8+ T-cell response infollowing mouse tyrosinase DNA vaccination. Each point refers to
atients also underwent two peripheral blood draws at baseline one
the mean of both of these time-points. * Refers to patients with
Figure 6 CTLA-4 blockade induced tyrosinase-specific CD8+IFN-γ+ T cell responses. ICS was performed on PBMCs from Patient Tyr-25 at
various time-points. He developed a tyrosinase-specific CD8+IFN-γ+ T cell response following vaccination. Subsequently, he developed recurrent
disease and was treated with ipilimumab. A persistent tyrosinase-specific CD8+IFN-γ+ response was noted prior to ipilimumab therapy, which
increased with ipilimumab therapy and peaked after the second dose (at Week 7).
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reactive cells (Figure 7A) and IFN-γ+ cells (Figure 7B).
This patient also had a rapid expansion of NY-ESO-1
specific CD4+IFN-γ+ T cells after vaccination.
Discussion
In this phase I study, we demonstrated that a mouse Tyr
DNA vaccine could be safely administered via in vivo EP to
melanoma patients. The only common toxicity was grade
1 injection site reaction in 46% of patients. Six of 15
patients (40%) in the 1.5 mg dose cohort developed Tyr-
reactive CD8+ T cell responses following stimulation,
defined by a ≥3 standard deviation increase in baseline
reactivity by tetramer or ICS assays. We didn’t detect Tyr-
reactive CD8+ T cell response in 0.2 mg and 0.5 mg dose
cohort patients. 4 HLA-A*01 positive experienced an
increase in the frequency of Tyr-specific tetramer-reactive
CD8+ T cells following vaccination. Three also had an
increase in Tyr-reactive CD8+ IFN-γ+ T cells; one patientFigure 7 Mouse tyrosinase DNA vaccination and subsequent NY-ESO-1
have baseline seropositivity for NY-ESO-1. Thawed PBMCs from pre- and po
overlapping peptides before tetramer analysis and ICS. Following vaccinatio
reactive CD8+ T cells and (B) NY-ESO-1 specific CD4+ and CD8+ IFN-γ+ T cehad an increase in both tetramer-reactive and CD8+ IFN-
γ+ T cells. 6 of 21 (28.6%) patients had an increase either in
Tyr-reactive tetramer-reactive and/or CD8+IFN-γ+ T cells
following vaccination. The fact that all six melanoma pa-
tients with a detectable Tyr-reactive T cell response re-
ceived the 1.5 mg dose provides preliminary indications of
a potential dose response. Results from other clinical test-
ing suggest that increases in DNA dose may offer an av-
enue to further enhance the magnitude and breath of
immune response [29]. However, it is also important to
note that, due to the limited number of epitopes repre-
sented within the peptide pool and absence of HLA-A*24
tetramer reagents, the immunologic responses detected
may underestimate the overall number of patients develop-
ing increased anti-Tyr immune reactivity.
Although differences in study design and patient popula-
tion enrolled in our pINGmuTyr studies conducted to date
precludes direct comparative analysis, the results obtained
in the present study from analysis of a population of HLA-specific tetramer and IFN-γ response. Patient Tyr-2 was known to
st- pINGmuTyr vaccination were cultured for 10 days with NY-ESO-1
n, there was an increase in (A) HLA/B*35 NY-ESO-194-102 tetramer-
lls.
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similar to our previous study, where the pINGmuTyr and
pINGhuTyr DNA vectors were administered via the IM
route to HLA-A*02 positive patients. In that study, 7 of 18
(39%) HLA-A*02 positive patients experienced an increase
either in Tyr-reactive tetramer or CD8+IFN-γ+ T cells fol-
lowing vaccination [20]. However, in the current study,
only tetramer responses to two HLA-A*01 epitopes could
be examined in 14 of the 21 evaluable patients, potentially
underestimating responses to other unassessed epitopes
presented by other HLA types. Moreover, it is unclear what
effect the monovalent immunization against muTyr alone
performed in the present study may have had on the mag-
nitude and frequency of response, especially with the pres-
ence of point mismatches between the human and murine
sequences in one of the two HLA-A*01 epitopes and the
single HLA-A*24 epitope included in the peptide pool used
for immunogenicity analysis.
We have also previously used polyfunctional cytokine re-
sponses – combinations of IFN-γ with MIP-1β, TNF-α and
CD107a – to quantify the “quality” of the immune re-
sponse [33,34]. While polyfunctional CD8+ T cell responses
were seen in this trial, they were not as qualitatively robust
as in two of our previous DNA vaccination trials with IM
injection of a mouse and human gp100 DNA vaccine or
with granulocyte-macrophage colony-stimulating factor
DNA and a tyrosinase and gp100 peptide vaccine [35]. The
results of the current trial were comparable to a recent trial
of a gp100 DNA vaccine via PMED [22].
Our group has previously reported that ipilimumab
therapy can augment humoral and cellular immune re-
sponses against different melanoma-associated tumor
antigens, including gp100 and NY-ESO-1, a prototypical
cancer-testis antigen, whose expression is restricted to
the testes and certain malignant tissues, including
melanoma [34,36]. Here, we observed a similar pheno-
menon, where a Tyr-reactive CD8+IFN-γ+ T cell re-
sponse induced by vaccination was subsequently
enhanced by the administration of two doses of ipilimu-
mab six months later for recurrent disease. NY-ESO-1 is
relatively immunogenic and baseline immune responses
have been reported in melanoma patients. It has previ-
ously been noted by our group and others that humoral
and T-cell mediated responses to NY-ESO-1 are highly
correlated [37]. As such, we were interested in studying
the impact, if any, of the pINGmuTyr vaccine on
NY-ESO-1 specific CD8+ T cell responses in a patient
with baseline NY-ESO-1 seropositivity. Although a Tyr-
specific immune response could not be demonstrated
following stimulation with the limited peptide epitope
pool used in our assays, this patient was the only person
in the study to develop vitiligo. To our surprise, she de-
veloped a robust NY-ESO-1 specific CD4+ and CD8+ T-
cell response by tetramer staining and ICS followingvaccination. Such an observation of “epitope spreading”
suggests that vaccination could potentially induce im-
mune responses not only against the target protein but
also potentially against other immunogenic components
of the malignant cell. This process may occur when vac-
cination generates a cytotoxic immune response that
leads to apoptosis of the malignant cell and the release
of cellular contents that may then be processed by APCs
to generate additional immune responses against other
targets. Vaccination may also generate an inflammatory
milieu at sites of disease, providing costimulatory signals
necessary for the recruitment and activation of antigen-
specific effector cells.
Unfortunately, the augmentation of Tyr-reactive immune
responses by ipilimumab and the induction of NY-ESO-1
specific responses by the pINGmuTyr vaccine respectively
in the patients above did not translate into clinical benefit.
The former developed recurrent disease five months after
vaccination and died within six months of starting ipilimu-
mab; the second patient developed recurrence after the
completion of five vaccinations. Numerous possibilities
may explain this discrepancy and highlight the challenges
of successful vaccine development, including the downreg-
ulation of cancer-specific antigens to permit malignant
cells to escape immune detection and destruction or the
elicitation of diverse mechanisms, e.g. regulatory T cells
that suppress the immune system [38].
The relative inefficacy of a monovalent vaccine – at
least one based on gp100 – is suggested by the phase III
trial of ipilimumab, in which patients received ipilimu-
mab or a gp100 peptide vaccine or the combination.
Both ipilimumab arms (alone or with gp100 vaccine)
had superior overall survival compared to the vaccine-
only arm. However, there was no difference between the
ipilimumab arms, suggesting minimal benefit from the
vaccine. Hence, this seminal phase III trial represents a
significant advancement in the treatment of refractory
melanoma, is an important triumph in the field of
immunotherapy but also highlights the significant chal-
lenges to the successful development of a melanoma
vaccine.
Conclusions
To date, our group has evaluated peptide and DNA vac-
cines against gp100 and/or tyrosinase delivered via the
IM, PMED or EP route. Within the limitation of the
heterogeneous study designs (i.e. variation in HLA types
enrolled, testing of regimens combining syngeneic and
xenogeneic antigens vs. xenogeneic alone), existing
immunogenicity assays (possible underestimation of
immune response based on the scope of the peptide pool
used for assessment) and small patient numbers in-
volved, all of these approaches appear to produce
antigen-specific immune responses and none appears
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dose-dependent immune response in this study. As we
and others survey the field, possible future trials may
involve further optimization of the vaccine and a multi-
valent vaccine against such targets as Tyr, gp100 and
NY-ESO-1. Targeting multiple antigens expressed on
melanoma cells may create a more immunogenic vaccine
that also decreases the ability of the malignant cells to es-
cape immune detection and destruction. In addition, the
combination of such a multivalent vaccine with ipilimu-
mab remains an attractive proposition. While the phase
III trial above involved the simultaneous administration
of vaccine and ipilimumab, the anecdotal observation
here and elsewhere by our group suggests a sequential
administration of vaccine followed by ipilimumab may




All patients were diagnosed with stage IIB-IV malignant
melanoma, histologically confirmed at the Memorial
Sloan-Kettering Cancer Center (MSKCC). Patients had
undergone prior surgical resection of primary or recur-
rent disease, were disease-free and had either declined
adjuvant IFN-α therapy or had previously developed re-
currence while on it. Additional eligibility criteria in-
cluded a Karnofsky performance status ≥ 80%, HLA-A1,
-A2, -A24 or -B35 positivity, the absence of detectable
brain metastases and adequate organ and bone marrow
function. Exclusion criteria included prior chemother-
apy, vaccination using tyrosinase DNA sequence, protein
or peptides, systemic immunosuppressive therapy, sur-
gery or radiotherapy within four weeks of study entry,
active autoimmune disease other than vitiligo, patient
with a history of syncope and/or seizures, and women
who were pregnant or < 3 months post partum or nurs-
ing. The study (NCT00471133) was reviewed and
approved by the MSKCC Institutional Review Board and
all patients provided informed consent.
Study design and treatment plan
Cohorts of three patients were sequentially accrued to
three dose levels of the mouse tyrosinase pINGmuTyr
plasmid construct by in vivo EP. 0.2, 0.5 or 1.5 mg of
plasmid DNA was injected every three weeks for a total
of five doses. Treatment was discontinued upon the de-
velopment either of dose-limiting toxicity (DLT) or of
recurrent disease requiring systemic treatment or radi-
ation therapy. DLT was defined as any grade ≥3 toxicity
or grade ≥ 2 allergic/immunologic toxicity, as per the
Common Terminology Criteria for Adverse Events, ver-
sion 3.0. With no DLT observed at any of the tested
dose levels, study enrollment was expanded at the1.5 mg plasmid DNA dose level using the same adminis-
tration regimen until a total of 15 subjects evaluable for
immunogenicity were enrolled at that dose level.
DNA vaccine construct
Mouse Tyr plasmid DNA was previously sequenced and
introduced into the pING vector by our group [39]. The
pINGmuTyr construct has been extensively tested in
both pre-clinical studies and clinical trials [17,20]. This
vector is in accordance with the FDA’s Points to Con-
sider for DNA vaccination. Clinical-grade pINGmuTyr
DNA was prepared by the MSKCC GMP compliant
Gene Transfer Core Facility and tested for endotoxin,
sterility and animal safety. The vaccine was administered
IM at a tissue site with intact lymphatic drainage. It was
administrated as a single injection for each time point.
No injection was given at a location in which the drain-
ing lymph nodes had been removed. The site of
immunization was alternated for each of the immuniza-
tions (e.g. left deltoid for the first, third and fifth and
right deltoid for the second and fourth). The vaccine
was administered using an EP system appropriate for IM
DNA delivery in the clinical setting provided by Ichor
Medical Systems, Inc. (San Diego, CA), according to the
manufacturer’s instructions. Immediately after the injec-
tion, a series of brief electrical pulses was applied to the
local tissue. The stimulation lasted for about 0.5 seconds
and resulted in localized contractions of the muscles at
the injection site.
Evaluations at baseline and during therapy
At baseline, a complete history and physical examination
was performed, along with a baseline ophthalmologic
examination to exclude pre-existing retinal or choroidal
disease. Routine blood work, chest imaging (X-ray or
CT) and a brain MRI were also obtained. Patients with a
history of resected metastatic disease also underwent ap-
propriate radiographic imaging to ensure they were
disease-free at time of study entry.
For immune function monitoring, blood samples were
drawn one week before and immediately prior to the
first vaccination and at Weeks 10 and 16, which corre-
sponds to after the third and fifth doses respectively. To
ensure the acquisition of a sufficient quantity of periph-
eral blood mononuclear cells (PBMC), leukopheresis was
performed at baseline and Week 16, if possible. In
addition, patients underwent clinical and radiologic
monitoring as indicated to assess for disease recurrence.
Immune function monitoring
Tetramer and intracellular cytokine staining (ICS) assays
were performed using multiparametric flow cytometry, as
previously described [33,40]. For this initial analysis, we se-
lected eight well characterized CD8+ T cell epitopes of
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ture, and validated the pool of these peptides for in vitro T
cell culture. Briefly, thawed PBMCs were incubated at a 1:1
ratio with irradiated autologous PBMCs pulsed with the fol-
lowing peptide pool at 10 μg/ml each: HLA-A1-restricted
TYR146-156 (SSDYVIPIGTY) and TYR243-251 (KCDICT-
DEY); HLA-A2-restricted TYR1-9 (MLLAVLYCL), TYR8-17
(CLLWSFQTSA) and TYR369-377 (YMDGTMSQV); HLA-
A24 restricted TYR206-214 (AFLPWHRLF); HLA-B35
restricted TYR309-320 (TPRLPSSADVEF) and; HLA-B44
restricted TYR192-200 (SEIWRDIDF) (JPT Peptide Tech-
nologies, Berlin, Germany).
Cells were harvested at Day 10 and analyzed immedi-
ately by tetramer staining. For ICS, cells were addition-
ally incubated for 20 minutes with PE-Cy5-CD107a
(5 μl/ml; BD Pharmingen) prior to re-stimulation with
the preceding tyrosinase peptide pool for 2 hours. Five
μg/ml each of Brefeldin A and monensin (BD Biosci-
ences, San Jose, CA) were then added for another
4 hours. The following tetramers and fluorochrome-
labeled antibodies were used: HLA-A*0101-restricted
TYR146-156 (SSDYVIPIGTY) and TYR243-251 (KCDICT-
DEY) tetramer (Tetramer Core, Lausanne Branch, Ludwig
Institute of Cancer Research, Lausanne, Switzerland), PE-
Cy7-CD3, APC-CD27, PerCPCy5.5-CD28, APC-Interleukin
(IL)-2, PE-Macrophage inflammatory protein (MIP)-1β, and
FITC-Interferon (IFN)-γ (BD Pharmingen, San Jose, CA),
Pacific blue-CD3, APC-AF750-CD8, PE-Cy7-Tumor necro-
sis factor (TNF)-α (eBioscience, San Diego, CA), ECD-CD4,
ECD-CD45RA (Beckman Coulter Inc., Fullerton, CA)
and FITC-CCR7 (R&D Systems, Minneapolis, MN). Cells
were analyzed using a CYAN-ADP flow cytometer
with Summit software (Dako Cytomation California Inc.,
Carpinteria, CA). Analysis was performed using FlowJo
software (version 9.1; TreeStar, Inc., Ashland, OR).Statistical analysis
A T cell response at any post-vaccination time-point was
considered positive if it was ≥3 standard deviations greater
than the mean value at baseline and had an absolute value
>0.1%. Differences between groups were analyzed using
Fisher’s exact test. Progression-free survival (PFS) and over-
all survival were estimated using the Kaplan-Meier method.Abbreviations
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